Document |
Document Title |
WO/2023/205802A2 |
Senescent cells are implicated in aspects of age-related decline in health and contribute to many diseases. Cells can be transformed into a senescent state upon prolonged exposure to the Senescence-Associated Secretory Phenotype (SASP) f...
|
WO/2023/205099A2 |
Here, we describe an infant with congenital dilated cardiomyopathy (cDCM) whose impaired cardiac function and disrupted sarcomere and mitochondria structures were modeled using induced pluripotent stem cells (iPSCs). The causal gene enco...
|
WO/2023/205785A2 |
The present disclosure generally relates to compositions and methods for targeting pro-survival signaling hubs in anoikis-resistant cells, such as anoikis-resistant cancer cells. Embodiments also include methods of changing morphology of...
|
WO/2023/201873A1 |
Disclosed are a BODIPY-based diamond-shaped metal ring, and a method for preparing same, and use thereof in near-infrared emission. According to the present invention, a BODIPY-based 120-degree bipyridine BODIPY ligand molecule 1 having ...
|
WO/2023/202092A1 |
Disclosed in the present invention are a nanoparticle capable of releasing carbon monoxide in a responsive manner, a preparation method therefor and the use thereof. The nanoparticle comprises a shell and an inner core, wherein the shell...
|
WO/2023/204581A1 |
The present invention relates to a three-dimensional hydrogel composite having cancer cell targeting and cancer cell killing effects, and a method for manufacturing same, and more specifically, to: a three-dimensional hydrogel composite ...
|
WO/2023/201312A2 |
The present application provides compounds and methods for treating ocular fibrotic pathologies, including using dopamine D2 receptor antagonists for treating proliferative vitreoretinopathy.
|
WO/2023/196405A1 |
Boronated prodrugs have been developed that are particularly advantageous for use in boron proton capture therapy (BPCT) and boron neutron capture therapy (BNCT). Cancer-targeting moieties, such as heptamethine cyanine dyes (HMCDs), are ...
|
WO/2023/196086A2 |
The present invention relates to combination therapies for treating cancers associated with genetic alterations of the MAPK pathway and/or EGFR In particular, the present invention relates to methods of treating cancer in a subject in ne...
|
WO/2023/196218A2 |
The present invention relates to combination therapies for treating cancers associated with genetic alterations of the MAPK pathway and/or EGFR. In particular, the present invention relates to methods of treating cancer in a subject in n...
|
WO/2023/196978A2 |
Provided herein are methods of identifying a subject with prostate cancer (such as a human or veterinary subject) who will respond to enzalutamide therapy. In particular examples, the methods can determine with high accuracy whether a su...
|
WO/2023/196584A2 |
The application relates to methods for treating chronic pain involving administering to a subject in need thereof a therapeutically effective amount of an inhibitor of endocytosis.
|
WO/2023/196821A2 |
The use of GUCY2C agonists in combination with PDE3 inhibitors in methods of treating the individual who has been identified as experiencing chronic visceral pain or in methods of suppressing appetite are disclosed. Compositions or kits ...
|
WO/2023/196891A2 |
The present invention provides a method for increasing the efficacy of an anticancer therapy by administering to a subject in need thereof at least one compound that at least partially blocks the activity of a bacterial DnaK, and pharmac...
|
WO/2023/196820A2 |
The present disclosure provides, among other things, specific doses of an ENPP1 agent for in vivo treatment of an ENPP1 deficiency, such as for treatment of Generalized Arterial Calcification of Infancy (GACI), Autosomal Recessive Hypoph...
|
WO/2023/196952A2 |
Provided herein is a method for treating a disorder ameliorated by muscarinic receptor activation in a patient in need thereof, comprising administering to the patient a muscarinic orthosteric agonist, such as xanomeline and/or a salt th...
|
WO/2023/196576A2 |
This invention discloses methods of diagnosing and compositions for treating a human subject suspected of having a neurological or hematological disease. Also disclosed are proteins which serve as effective biomarkers for confirming the ...
|
WO/2023/193416A1 |
The present invention relates to the field of biomedicine, and specifically, discloses a near-infrared-responsive injectable microsphere capable of treating a cancer by combining chemotherapy with photothermal therapy and a method for pr...
|
WO/2023/194896A1 |
5-amminolevulinic acid and/or the salts thereof for use in mandibular bone regeneration, in combination with the application of light radiation, wherein the bone regeneration is determined by an increase in the proliferation of osteoblas...
|
WO/2023/192955A2 |
Disclosed herein are compositions and methods for treating cancer. The methods can comprise administrating to a subject with cancer a therapeutically effective amount of an oncolytic virus and a therapeutically-effective amount of a nucl...
|
WO/2023/133058A9 |
Disclosed are methods of treating an ocular disease associated with retinal ischemic injury in a subject comprising administering to the subject a p75NTR modulator, a MSC comprising decreased p75NTR expression or activity or a MSC secrel...
|
WO/2023/192938A2 |
The current disclosure provides for methods for diagnosing, prognosing, and treating cerebral cavernous malformations (CCMs). Also provided are methods for determining the efficacy of therapeutic treatments for CCM, such as those that ma...
|
WO/2023/187176A1 |
The invention concerns an in vitro or ex vivo method for delivering a cargo into a cell, the method comprising: - contacting a cell with one or more photoresponsive organic particles and a cargo, wherein the organic particle is selected ...
|
WO/2023/186737A1 |
Photodynamic light therapy apparatus and methods for treating oral disease are disclosed where one method for reducing or eliminating microbial biofilm or plaque and inflammation in a microbial infected area of the mouth generally compri...
|
WO/2023/192815A2 |
Methods of data analysis, methods of detection, methods of treatment, compositions, and kits associated with treatment of diarrheal disorders are disclosed herein. Inventive concepts disclosed herein can assist stake holders in relieving...
|
WO/2023/192988A2 |
The technology described herein is directed to immune modulatory agents and methods of use. In some aspects, described herein are agents that modulate IL-17a/IL-17 receptor- induced signalling and/or IL-17f/IL-17 receptor-induced signall...
|
WO/2023/192220A2 |
The present disclosure provides methods and systems for diagnosing and treating fibromyalgia in a patient. In one method, an oxygenation level at a muscle location is obtained for the patient; and fibromyalgia is diagnosed in the patient...
|
WO/2023/192639A2 |
In one aspect, methods of treating cancer are provided that comprise: administering to a subject a composition comprising a therapeutically effective amount of: a first agent which inhibits programmed death 1 (PD-1) expression or functio...
|
WO/2023/192779A2 |
The present application relates to the prevention and treatment of respiratory illnesses due to RNA virus infection in patients in need thereof. The application includes compositions of matter, pharmaceutical compositions, combinations, ...
|
WO/2023/192880A2 |
Disclosed herein are methods for treating, ameliorating and/or preventing fibrodysplasia sssificans progressiva (FOP) in a subject in need thereof. The methods include downregulating matrix metalloproteinase 9 (MMP-9) level and/or activi...
|
WO/2023/192653A1 |
The present disclosure provides photocleavable rhodamine probes that facilitate live- and fixed-cell immunofluorescence. The ultra-fast spirocyclization of the dye following cleavage depletes the fluorescence signal, enabling cyclic mult...
|
WO/2023/182317A1 |
The purpose of the present invention is to provide a novel compound which can serve as a component of a boron pharmaceutical agent. The present application provides a boron-containing modified polyrotaxane comprising a plurality of cyclo...
|
WO/2023/179866A1 |
The present invention relates to means for transiently disrupting the neurovascular barrier of a human. More particularly, the invention relates to ultrasound contrast agent for use in treating Amyotrophic Lateral Sclerosis (ALS) in a su...
|
WO/2023/178878A1 |
A microneedle patch for enhancing an accumulation of protoporphyrin IX in a solid tumor and a preparation method therefor. The method comprises the steps of: dissolving albumin in a Dulbecco's culture medium, using the albumin as a templ...
|
WO/2023/183776A2 |
The present disclose provides methods for treating neuroinflammation. Compositions having therapeutic agents targeted to interfering with succinate/succinate receptor signaling are administered to reduce or ameliorate neuroinflammation. ...
|
WO/2023/183706A2 |
The technology relates in part to methods of selecting for and/or treating subjects having cancer, where the subjects are identified as having at least one genetic structural variant that renders them suitable candidates for a treatment ...
|
WO/2023/178810A1 |
The present invention belongs to the technical field of drug-targeting carriers. Disclosed are a co-drug-loaded cell microparticle formulation and a preparation method therefor. The co-drug-loaded cell microparticle formulation comprises...
|
WO/2023/183247A2 |
The present invention provides for methods of treating biogenic amine related conditions. Further provided are methods of detecting biogenic amine related conditions, and selection of treatment for patients in need thereof.
|
WO/2023/183936A2 |
The present invention provides methods, compositions, and combinations for treating cancer via combined use of a compound that forms a covalent bond with a kinase or pseudokinase, or a pharmaceutically acceptable salt thereof, and at lea...
|
WO/2023/178964A1 |
The present invention relates to a method for promoting a drug molecule to reach an action target in a tumor cell, a method for promoting delivery of an endogenous tumor antigen and tumor DNA to a DC, a method for activating a STING path...
|
WO/2023/178199A2 |
The present disclosure provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of certain circulating proteins. In another aspect, the present disclosure provides bifunctional compounds that can...
|
WO/2023/178240A2 |
Provided herein are novel therapeutic applications of Pyk2 (PTK2B) inhibitors to treat low bone mineral density and/or osteoporosis and to treat, prevent, or delay the progression of neurodegenerative disorders such as Alzheimer's disease.
|
WO/2023/176872A1 |
Provided is a pharmaceutical composition to be used for radiotherapy that comprises a compound represented by formula (I) [wherein: R1 is an aryl group substituted by a substituent selected from an iodine atom, etc., wherein the aryl gro...
|
WO/2023/177560A2 |
The invention provides novel triplet-triplet annihilation upconversion nanoparticles as background free self-standing biological sensors, and devices and methods thereof.
|
WO/2023/173824A1 |
Disclosed in the present invention are a hydrophobic methylene blue fluorescent dye, and a preparation method therefor and the use thereof. The hydrophobic methylene blue fluorescent dye has a structural formula as shown in formula (I), ...
|
WO/2023/177841A2 |
A method is provided for reducing concurrent use of stimulant medications and alcohol. In an example, the method comprises administering to the subject a combination product that includes an effective amount of one or more stimulant medi...
|
WO/2023/178179A2 |
Described herein is a bi-functional compound for removing macrophage migration inhibitory factor (MIF) or immunoglubin G (IgG). Further described herein is a pharmaceutical composition which comprise these bi-functional compounds. Furthe...
|
WO/2023/178331A2 |
An anti-tumor agent is provided to a patient to increase a susceptibility of a tumor within the patient to harmonic excitation. Ultrasonic transducers of a wearable are driven to direct a therapeutic ultrasound signal into tissue of the ...
|
WO/2023/173131A2 |
The disclosure relates to the use of phosphodiesterase 1 (PDE1) inhibitors alone or in combination with immune checkpoint inhibitor therapies for the treatment of breast cancer, including for promoting antitumor immunity and mitigating t...
|
WO/2023/173036A2 |
The present disclosure relates to the use of MASP-2 inhibitors and/or MASP-3 inhibitors and compositions comprising the same for treatment of sickle cell disease, including treatment, reduction, and/or prevention of sickle cell disease s...
|